Bannoura SF et al. suggested that oncogenic KRAS signaling is critical for both the initiation and maintenance of pancreatic cancer; therefore, it is an ideal target for therapy (Bannoura et al., 2021). The gene discussed is KRAS; the disease is pancreatic neoplasm.